Elligo Health Research, the largest healthcare-enabling research organization, today announced that Dawn Sauro has been named as Elligo’s Chief Operating Officer (COO) to help further the company’s growth, efficiency, and mission of optimizing the intersection of healthcare and research through direct access to patients, new technology, and custom research practice management solutions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230105005290/en/

Dawn Sauro is Elligo Health Research’s new Chief Operating Officer. (Photo: Business Wire)

Sauro most recently served as Elligo’s Executive Vice President, Research Strategy. In her new role as Elligo’s COO, she brings more than 30 years of drug and device development experience, including working for sites, sponsors, and clinical research organizations (CROs). Prior to joining Elligo, Sauro was Chief Development Officer at Clinipace Clinical Research (now Caidya) where she grew the organization to be a trusted partner for sponsors across a variety of therapeutic areas. Prior roles also included President, Development Innovations at Sarah Cannon and Senior Vice President and General Manager, Hematology/Oncology at inVentiv Health (now Syneos).

“Dawn is a drug development and clinical research business leader with deep subject matter expertise across a broad spectrum of therapeutic areas, but specifically brings vast knowledge in hematology and oncology,” said Elligo CEO John Potthoff. “She is a valued member of company leadership with decades of industry insight, client relationships, and an understanding of unique needs that help sponsors and clinical research sites drive results.”

Sauro said, “I look forward to continuing in this new leadership role with Elligo, but also continuing to focus on delivering outcomes that move us all closer to our ultimate goal — providing everyone with easier access to participate in clinical research.”

About Elligo Health Research^®

Elligo Health Research accelerates clinical trials through healthcare with access to over 150 million known patients and their HIPAA-compliant healthcare data, our IntElligo^® Research Stack technology, and our PatientSelect^® identification and engagement model. Coupled with the largest Known Patient Access Network, Elligo’s Site Solutions enable healthcare practices and research sites to participate in clinical trials. By adaptive engagement of known patients and physicians, we accelerate the development of new pharmaceutical, biotechnology, and medical device and diagnostic products.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005290/en/

A 30+ year industry veteran and @ElligoHealth Executive Vice President, Research Strategy, Dawn Sauro, was appointed as Elligo’s new Chief Operating Officer.